Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph subcutaneous, launched Q3 2025) — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment & Product Sales Footnote
Latest, Q2 2026
463
Period ended Jun 30, 2026
Change on a year earlier
–
0 in Q2 2025
History
4 quarters
Since Q1 2025
Sources
2
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph subcutaneous, launched Q3 2025) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 463 | – | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 128 | – | Form 10-Q (filed 2026-05-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 0 | – | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 0 | – | Form 10-Q (filed 2026-05-04) ↗ |
Breakdown
What makes up keytruda qlex (pembrolizumab and berahyaluronidase alfa-pmph subcutaneous, launched q3 2025) — worldwide sales ($m)
Cite this data
StockData. (2026). Merck Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph subcutaneous, launched Q3 2025) — Worldwide sales ($M) ($M), quarterly Q1 2025–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_keytruda_qlex
See every metric in the Merck KPI table. Data updated Oct 26, 2026.